Skip to content

Rechargeable implantable spinal cord stimulation system for the treatment of chronic intractable pain: a prospective, multicenter, superiority, controlled trial

Rechargeable implantable spinal cord stimulation system for the treatment of chronic intractable pain: a prospective, multicenter, superiority, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066536
Enrollment
Unknown
Registered
2022-12-08
Start date
2022-12-08
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic, intractable pain

Interventions

Experimental group:stimulation continued in the random period

Sponsors

The First Affiliated Hospital of Medical School of Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Testing period: (1) Aged >= 18 years, no gender limit; (2) Chronic intractable pain that lasts at least 3 months and refractory to the conservative therapies; (3) VAS assessment of pain degree score>=5; (4) Able to understand the purpose of the protocol, voluntarily participate and sign the informed consent. 2. Long-term implantation period: Pain VAS scores in the test period improved by more than 50% compared with baseline period.

Exclusion criteria

Exclusion criteria: 1. Testing period: (1) Severe mental or cognitive disorders, cannot cooperate during surgery and post-operative programming; (2) Severe cardiopulmonary insufficiency, coagulopathy or puncture site infection; (3) Subjects with drug abuse; (4) Spinal anatomic abnormalities prevented the electrodes from being implanted; (5) Subjects who are pregnant or breastfeeding; (6) Subjects who are participating in other clinical trials, not yet out of the group; (7) Other inappropriate situations determined by investigators. 2. Long-term implantation period: (1) Subjects who cannot tolerate SCS; (2) Other inappropriate situations determined by investigators.

Design outcomes

Primary

MeasureTime frame
Change in pain visual analogue scale (VAS) score from baseline;

Secondary

MeasureTime frame
Changes in VAS scores from baseline;Response rate was reduced by >=50% from baseline VAS score;Improvement rate of VAS score (VAS score <=4);Beck depression inventory for depression evaluation;Brief pain inventory (BPI);The European five-dimensional health scale (EQ - 5 D - 5 L);Short form McGill pain questionnare-2 (SF-MPQ-2);Pittsburgh sleep quality index (PSQI);Drug usage;Investigator's evaluation of operational performance of investigational equipment;

Countries

China

Contacts

Public ContactFeng Zhiying

The First Affiliated Hospital of Medical School of Zhejiang University

13989881666@163.com+86 13989881666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026